Well, that's how biotech start-up stock work. The pps will increase based on clinical trial update and if they are shit it will get smashed on the day of the announcement, it's as simple as that. It didn't and consolidated at 10c for month and touched 13c as well.
We know IMU is still heavily traded with a lot of shorter volumes and they were able to do the damage in the 8 months period waiting for further clinical trial update to drop the pps down to 5c. The release of excellent clinical trial update for Azer-Cel saw a spike from 5c to 8c but clearly the market doesn't care about this IP but are interested in VAXINIA and especially OASIS which is understandably given the market potential.
IMU Price at posting:
2.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)